ArticleJournal of global health2024
Association between sarcopenia and frailty in middle-aged and elder population: Findings from the China health and retirement longitudinal study.
Article in Journal of global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Simple Clinical Score Using Hemoglobin, Age, and BMI Effectively Predicts Possible Sarcopenia.Internal medicine (Tokyo, Japan) · 2026Article
- Frailty Index and Risk of Ischemic Stroke in China: Evidence from a Cohort Study, Disease Burden Analysis, and Mendelian Randomization.Healthcare (Basel, Switzerland) · 2026Article
- Sustained moderate to high triglyceride-glucose index level is associated with a lower risk of sarcopenia in middle-aged and elderly adults: a nationally representative cohort study.Lipids in health and disease · 2026Article
- Estimated Cardiorespiratory Fitness and Risk of Incident Frailty in Middle-Aged and Older Adults: A Cross-National Longitudinal Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Network pharmacology analysis and in vitro verification of the anti-sarcopenia effects of formononetin.Bioresources and bioprocessing · 2025Article
- Probable respiratory sarcopenia and 9-year mortality in community-dwelling older adults: the first longitudinal evidence from the CHARLS.Scientific reports · 2025Article
- Definition and diagnosis of sarcopenia: Asia-Pacific perspectives.Osteoporosis and sarcopenia · 2025Review
- Association Between Oral Health and Probable Sarcopenia in Older Adults: A Cross-Sectional Study.International journal of general medicine · 2025Article
- Association of triglyceride-glucose index and diabesity: evidence from a national longitudinal study.Lipids in health and disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between sarcopenia and frailty among middle-aged and elder adults remains unclear. This study conducted a cross-sectional and longitudinal analysis to investigate the association of sarcopenia and frailty in the middle-aged and elder Chinese population. Methods: Our data were drawn from the China Health and Retirement Longitudinal Study. Sarcopenia status was assessed according to the Asian Working Group for Sarcopenia 2019 criteria and categorised into: no sarcopenia, possible sarcopenia, sarcopenia, and severe sarcopenia. A 38-item deficit-accumulation frailty index was constructed to assess frailty trajectories at each visit. Generalised linear regression models were performed to analyse the cross-sectional associations between sarcopenia and frailty index. The Group-based trajectory modelling was adopted to identify potential frailty trajectories, and we then examined the associations of sarcopenia and frailty trajectories using logistic regression analysis. Results: A total of 13 218 participants were enrolled in the cross-sectional analysis and 4200 individuals were included in the longitudinal study. The cross-sectional study found that possible sarcopenia (regression coefficient (β) = 0.76; 95% confidence interval (CI) = 0.64-0.87, P < 0.001), sarcopenia (β = 0.56; 95% CI = 0.37-0.75, P < 0.001) and severe sarcopenia (β = 1.35; 95% CI = 0.97-1.73, P < 0.001) were significantly associated with higher frailty index. The longitudinal study indicated that participants with possible sarcopenia (odds ratio (OR) = 2.46; 95% CI = 1.77-3.42, P < 0.001), sarcopenia (OR = 1.87; 95% CI = 1.27-2.74, P < 0.001) and severe sarcopenia (OR = 6.57; 95% CI = 3.14-13.77, P < 0.001) had a higher risk of accelerated progression of frailty compared to those with no sarcopenia. Conclusions: Possible sarcopenia, sarcopenia, and severe sarcopenia were associated with higher levels of frailty and accelerated progression of frailty. Therefore, clinical medical professionals should pay more attention to frailty status in individuals who have possible sarcopenia and sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.